Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

CMC Drug Product Consulting ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   31.1% 6.7% 2.5% 2.2% 4.5% 16.5% 17.6% 17.4%   Credit score (0-100)   1 37 63 64 46 10 9 9   Credit rating   C BBB BBB BBB BBB BB B B   Credit limit (kDKK)   0.0 0.0 0.0 0.1 0.0 -0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   0.0 818 3,477 2,739 1,544 501 0.0 0.0   EBITDA   0.0 378 2,412 858 152 -849 0.0 0.0   EBIT   0.0 378 2,412 858 152 -849 0.0 0.0   Pre-tax profit (PTP)   0.0 370.1 2,430.5 890.9 182.5 -851.0 0.0 0.0   Net earnings   0.0 286.9 1,892.0 692.3 135.9 -666.8 0.0 0.0   Pre-tax profit without non-rec. items   0.0 370 2,431 891 182 -851 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   0.1 287 1,939 1,329 472 -463 -503 -503   Interest-bearing liabilities   0.0 2.1 2.0 2.0 2.0 624 503 503   Balance sheet total (assets)   0.1 441 2,667 1,678 608 282 0.0 0.0   Net Debt   -0.1 -429 -909 -348 -56.0 531 503 503     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   0.0 818 3,477 2,739 1,544 501 0.0 0.0   Gross profit growth   0.0% 0.0% 325.3% -21.2% -43.6% -67.5% -100.0% 0.0%   Employees   0 1 3 3 2 2 0 0   Employee growth %   0.0% 0.0% 200.0% 0.0% -33.3% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   0 441 2,667 1,678 608 282 0 0   Balance sheet change%   0.0% 441,299.0% 504.3% -37.1% -63.8% -53.7% -100.0% 0.0%   Added value   0.0 378.2 2,411.6 857.9 152.3 -848.6 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   0.0 1.0 2.0 3.0 4.0 -1.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   0.0% 46.3% 69.4% 31.3% 9.9% -169.3% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   0.0% 171.3% 156.8% 42.0% 16.5% -125.5% 0.0% 0.0%   ROI %   0.0% 261.6% 218.6% 55.8% 20.9% -154.6% 0.0% 0.0%   ROE %   0.0% 199.9% 170.0% 42.4% 15.1% -177.0% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   100.0% 65.0% 72.7% 79.2% 77.6% -62.2% -100.0% -100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   0.0% -113.3% -37.7% -40.6% -36.8% -62.6% 0.0% 0.0%   Gearing %   0.0% 0.7% 0.1% 0.1% 0.4% -134.9% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 788.6% 330.2% 1,098.7% 336.9% 0.8% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.0 2.8 3.7 4.8 4.4 0.4 0.0 0.0   Current Ratio   0.0 2.8 3.7 4.8 4.4 0.4 0.0 0.0   Cash and cash equivalent   0.1 430.6 911.0 350.0 58.0 92.9 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   0.1 281.2 1,933.2 1,323.7 467.3 -467.0 -251.3 -251.3   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 378 804 286 76 -424 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 378 804 286 76 -424 0 0   EBIT / employee   0 378 804 286 76 -424 0 0   Net earnings / employee   0 287 631 231 68 -333 0 0